Europe’s Treponema pallidum tests market is expected to witness steady growth, driven by the increasing burden of syphilis, growing concerns around delayed diagnosis, and expanding focus on sexually transmitted infections (STIs) surveillance and early disease detection. The resurgence of syphilis across multiple European countries is reinforcing the need for timely diagnostic interventions, supporting wider adoption of Treponema pallidum tests across hospitals, diagnostic laboratories, and sexual health settings. Amid these trends, the Treponema pallidum market in Europe is projected to grow at a compound annual growth rate (CAGR) of approximately 3% through 2036, according to GlobalData, a leading intelligence and productivity platform.
GlobalData’s latest report, “Treponema Pallidum Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2036,” reveals that Europe accounted for nearly 30% of the global Treponema pallidum market in 2025.
Sarvesh Kumar, Medical Devices Analyst at GlobalData, comments: “Europe’s Treponema pallidum tests market is gaining momentum as healthcare systems increasingly recognize the importance of early syphilis diagnosis in reducing long-term complications and transmission risks. The growing focus on preventive screening, particularly among high-risk and vulnerable populations, alongside expanding diagnostic accessibility, is expected to strengthen testing demand across the region.”
Congenital syphilis remains a major public health concern due to its association with severe neonatal complications and preventable adverse pregnancy outcomes. As healthcare authorities place greater emphasis on prenatal screening, surveillance, and timely intervention to curb disease transmission, the demand for Treponema pallidum tests is likely to increase across clinical and public health settings.
Kumar concludes: “While access to timely syphilis testing remains uneven in parts of Europe, the growing urgency around syphilis control and stronger focus on early diagnosis and timely intervention are expected to support the long-term expansion of the Treponema pallidum tests market in the region.”
